Biosimilars: considerations with low molecular weight heparins.
Jackson
Craig M
CM
Washington University School of Medicine, St Louis, Missouri, USA.
D000925:Anticoagulants / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight